April 21, 2026 | Read online

Early Morning Coverage: See Why (GCTK) Is in Our Focus Today

Any content you receive is for information purposes only. Always conduct your own research.

*Corrected Disclosure

*Sponsored

Market Maven Insights Initiates Coverage On GlucoTrack, Inc. (Nasdaq: GCTK) Starting This Morning—Tuesday, April 21, 2026

Don’t miss the next breakout — get real-time alerts sent straight to your phone!

Full Coverage Is Starting Early…

Consider Starting Your Own Research On (GCTK) While It’s Still Early…

April 21, 2026

Early Morning Coverage | See Why (GCTK) Is in Our Focus Today

Dear Reader,

Most people don’t think twice about how glucose is tracked, until they see how often it has to be managed.

A small patch.
Worn on the arm.
Replaced every 10–14 days.

For millions living with diabetes, that cycle is constant.

But GlucoTrack, Inc. (Nasdaq: GCTK) is working toward something very different, a fully implantable continuous blood glucose monitor designed to operate for years, without any external wearable.

No patch.
No routine replacements.
No visible device.

Instead, a system built for long-term, continuous monitoring beneath the skin.

With early human data already completed and an FDA IDE submission targeted for Q2 2026, the company is now entering a more critical stage of development—and beginning to draw attention.

Here’s where it gets interesting.

(GCTK) is developing a long-duration implantable solution that removes the need for traditional on-body CGM systems altogether—positioning it within a rapidly evolving segment of diabetes care.

That’s why (GCTK) is moving to the top of our watchlist heading into Tuesday, April 21, 2026.

For now, the name still appears to be under the radar, trading below $1 as of this week.

But the structure stands out.

(GCTK) has roughly 1.0M–1.8M shares outstanding, with a sub-1M public float—a setup that can react quickly as attention begins to build.

And we’ve already seen a glimpse of that.

Recently, (GCTK) made an approximate 53% move in under a week, climbing from around $0.65 on April 9 to $1.00 on April 13.

Now, with multiple factors starting to align, it’s beginning to show up on our radar.

That combination, a differentiated device, early human data, and a development timeline that is beginning to tighten, is what’s starting to bring (GCTK) into clearer focus for us.

In a space largely dominated by wearable systems, a company pursuing a fully implantable alternative naturally stands apart.

Layer in a tightly held float and a recent move that already showed this name can react quickly, and it becomes easier to see why attention could begin to shift.

In other words, this is no longer just a concept, it’s a developing story that may be entering a phase where the market starts paying closer attention.

With an FDA IDE submission targeted for Q2 2026 and a U.S. clinical trial expected in the second half of 2026, (GCTK) is positioning itself as a name to watch within the medtech diabetes space.

To understand why, it’s worth taking a closer look at what (GCTK) is building—and how its approach differs from the systems patients rely on today.

Inside (GCTK): The Technology and Strategy Driving Its Next Phase

GlucoTrack, Inc. (Nasdaq: GCTK) is a New Jersey–based medical technology company focused on developing next-generation solutions for diabetes management.

At the center of its pipeline is a Continuous Blood Glucose Monitor (CBGM)—a long-term, fully implantable system designed to measure glucose directly from the bloodstream rather than interstitial fluid. By targeting blood-based readings, the platform is built to reduce the lag time commonly seen with traditional wearable CGMs.

The system is being developed with a target lifespan of up to three years, minimal calibration requirements, and no external wearable component—addressing many of the friction points associated with patches, adhesives, and frequent sensor replacements.

This positions (GCTK) in a unique lane.

While most current solutions rely on short-duration, skin-mounted sensors lasting 10–14 days, and more invasive implantable options can be complex, (GCTK)’s approach is designed to bridge that gap with a long-duration, low-maintenance alternative.

From a progress standpoint, the company has already:

Completed a first-in-human study
Advanced follow-up feasibility work internationally
Secured three U.S. patents tied to its core technology
Established a U.S. clinical trial site and engaged a CRO

All of which leads into a key next step: an FDA IDE submission targeted for Q2 2026, marking a transition into the next phase of clinical development.

The Market Backdrop: A Growing Global Health Challenge

The scope of diabetes worldwide continues to expand at a significant pace.

According to the International Diabetes Federation, an estimated 589M adults are currently living with diabetes—a number projected to climb to 700M by 2045.

The economic impact is just as substantial. Global health expenditures tied to diabetes have reached approximately $1 trillion, representing a 338% increase over the past 17 years.

As both prevalence and costs continue to rise, the demand for more efficient, long-term management solutions is becoming increasingly critical.

Against that backdrop, the global CGM market was valued at approximately $13.3B in 2025 and is projected to grow to $31.4B by 2031 at a 15.4% CAGR, making it one of the fastest-growing segments in all of medical devices.

Today's market is dominated by wearable subcutaneous sensors from Abbott, Dexcom, and Medtronic—three companies that collectively controlled over 98% of 2025 shipments according to Mordor Intelligence.

But every one of their devices requires periodic on-body replacement.

(GCTK) is targeting the patient population that wants continuous monitoring without the daily or biweekly maintenance burden.

That represents a genuinely differentiated niche within a rapidly expanding market.

Clinical Progress & Regulatory Momentum

(GCTK)’s development pathway is now entering a more pivotal stage.

The company has already completed its first-in-human study, conducted in São Paulo, Brazil between December 2024 and January 2025, marking an important early step in validating its implantable system.

The 5-day in-hospital study enrolled 10 participants with Type 1 or Type 2 diabetes on intensive insulin therapy. Results were compelling: a Mean Absolute Relative Difference (MARD) of 7.7% across 122 matched pairs, a 99% data capture rate, and zero procedure- or device-related serious adverse events.

The study met all primary and secondary endpoints.

In July 2025, the company initiated a multicenter feasibility study in Australia at St. Vincent's Hospital in Melbourne.

Learnings from that study have been incorporated into product design iterations ahead of the U.S. program.

A U.S. clinical site has been secured, a CRO has been engaged, and the company confirmed it expects to file its Investigational Device Exemption (IDE) with the FDA in Q2 2026, targeting a U.S. trial launch in the second half of 2026, subject to FDA approval.

Strengthening the Foundation: IP Protection and Capital Strategy

In October and November 2025, the USPTO issued three critical patents for (GCTK)'s CBGM platform (Patent Nos. US 12,453,494, US 12,458,257, and US 12,458,258), covering proprietary sensor chemistry, intravascular lead design, and low-power electronics.

These patents protect the core innovations that differentiate (GCTK)'s system from both short-lived subcutaneous sensors and larger, more invasive implantable devices.

On the financial side, (GCTK) reported $7.4M in ca-sh and ca-sh equivalents as of December 31, 2025, up from $5.6M at the prior year-end, aided by a $4.0M private placement completed in December 2025.

Full-year 2025 R&D expenses were $9.8M, reflecting continued investment in product design, manufacturing, and preclinical work.

The company stated that existing cash is sufficient to fund its 2026 operating plan through at least the end of Spring 2026—covering the IDE submission.

Management has assembled a leadership team with deep backgrounds at Dexcom, Abbott, Senseonics, and Medtronic.

7 Reasons Why (GCTK) Is At the Top of Our Watchlist — Tuesday, April 21, 2026

Implantable Advantage: (GCTK) is developing a fully implantable continuous glucose monitor designed for multi-year use—eliminating the need for on-body wearables used in traditional systems.
Tight Float Structure: With fewer than 1.8M shares available to the public, the company maintains a small float that can respond quickly as interest builds.
Recent Action: The stock recently made an approximate 53% move in under a week, climbing from around $0.65 on April 9 to $1.00 on April 13.
Early Clinical Data: Initial results reported a 7.7% MARD, 99% data capture rate, and zero serious device- or procedure-related adverse events across 122 matched pairs.
Defined FDA Timeline: The company is targeting an IDE submission in Q2 2026, with a U.S. clinical trial planned for the second half of 2026, creating a clear near-term roadmap.
Patent Coverage: Three issued U.S. patents provide protection across key components of the platform, including sensor chemistry, intravascular design, and low-power electronics.
Expanding Market Opp: (GCTK) is targeting a segment within the CGM market projected to grow from approximately $13.3B in 2025 to $31.4B by 2031, focusing on long-term monitoring without frequent device replacement.

Take A Look At (GCTK) Before The Bell Rings…

When you zoom out, the setup here starts to come into focus.

(GCTK) is developing a fully implantable continuous glucose monitor designed for long-term use—without the external wearable component required by today’s standard systems.

That alone puts it in a different category.

Then there’s the structure.

With fewer than 1.8M shares available to the public, (GCTK) maintains a tight float that can react quickly as demand shifts. We’ve already seen a glimpse of that, with the stock making an approximate 53% move from ~$0.65 to $1.00 in under a week.

Behind the story, there’s also measurable progress. Early clinical data reported a 7.7% MARD, 99% data capture rate, and zero serious device- or procedure-related adverse events across 122 matched pairs.

Now layer in timing.

An IDE submission is targeted for Q2 2026, with a U.S. clinical trial expected in the second half of 2026, alongside three issued U.S. patents protecting key parts of the platform.

Put it all together, and (GCTK) is starting to look like a name worth watching more closely.

We’ll have all eyes on (GCTK) early this morning.

Take a look before the close—and keep an eye out for the next update.

Sincerely,
Tate Remington
Chief Editor, Market Maven Insights

^{MarketMavenInsights.com}^{(“MarketMavenInsights” or “MMI”) is owned by Source Coastal Media LLC, a multi member limited liability company. Data is provided from third-party sources and MMI is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MMI brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors.}

^{*CORRECTED DISCLOSURE}^{- Pursuant to an agreement between Source Coastal Media LLC and TD Media LLC, Source Coastal Media LLC has been hired for a period beginning on 04/20/2026 and ending on 04/21/2026 to publicly disseminate information about (GCTK:US) via digital communications. Under this agreement, TD Media LLC has paid Source Coastal Media LLC six thousand two hundred fifty USD (“Funds”). To date, including under the previously described agreement, Source Coastal Media LLC has been paid thirteen thousand seven hundred fifty USD (“Funds”). These Funds were part of the nineteen thousand USD funds that TD Media LLC received from a third party named Organized Noise LLC who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.}

^{Neither Source Coastal Media LLC, TD Media LLC and their member own shares of (GCTK:US).}

^{Please see important disclosure information here:}^{https://marketmaveninsights.com/disclosure/gctk-qcfgt/#details}